Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis receives EU approval for Jevtana prostate cancer treatment

Sanofi-aventis receives EU approval for Jevtana prostate cancer treatment

21st March 2011

Sanofi-aventis has been granted approval for a new Jevtana-based prostate cancer treatment to be commercialised in the EU.

The European Commission has ratified a new therapy option that combines the company's cabazitaxel-based drug with prednisone/prednisolone among patients with metastatic hormone-refractory prostate cancer (mHRPC) who have previously been treated with docetaxel.

This ruling was granted following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, which was based on its performance in clinical trials.

Jevtana now becomes the first approved agent that has been shown to extend overall survival rates in mHRPC patients who have proven unresponsive to docetaxel therapies.

Dr Debasish Roychowdhury, senior vice-president and head of the global oncology division at Sanofi-aventis, said: "The European approval of Jevtana offers new hope for patients across Europe with limited treatment options should their disease progress following first-line therapy."

Earlier this month, the company announced that Dr Richard Klausner is to be appointed as the new chairman of its Strategic Development and Scientific Advisory Council.ADNFCR-8000103-ID-800469403-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.